Rational Design of Broad Spectrum Antibacterial Activity Based on a Clinically Relevant Enoyl-Acyl Carrier Protein (ACP) Reductase Inhibitor
Open Access
- 1 June 2014
- journal article
- enzymology
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 289 (23) , 15987-16005
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health (T32GM092714, T32GM008444, GM102864, AI044639, AI070383, 1 S10 RR023680-1)
This publication has 74 references indexed in Scilit:
- Staphylococcus aureus FabI: Inhibition, Substrate Recognition, and Potential Implications for In Vivo EssentialityStructure, 2012
- Metabolic basis for the differential susceptibility of Gram-positive pathogens to fatty acid synthesis inhibitorsProceedings of the National Academy of Sciences, 2011
- Mechanism and inhibition of the FabI enoyl-ACP reductase from Burkholderia pseudomalleiJournal of Antimicrobial Chemotherapy, 2011
- A Slow, Tight Binding Inhibitor of InhA, the Enoyl-Acyl Carrier Protein Reductase from Mycobacterium tuberculosisJournal of Biological Chemistry, 2010
- A Medicinal Chemist’s Guide to Molecular InteractionsJournal of Medicinal Chemistry, 2010
- Mechanism and Inhibition of the FabV Enoyl-ACP Reductase from Burkholderia malleiBiochemistry, 2010
- Slow-Onset Inhibition of the FabI Enoyl Reductase from Francisella tularensis: Residence Time and in Vivo ActivityACS Chemical Biology, 2009
- Design and synthesis of 2-pyridones as novel inhibitors of the Bacillus anthracis enoyl-ACP reductaseBioorganic & Medicinal Chemistry Letters, 2008
- Clustal W and Clustal X version 2.0Bioinformatics, 2007
- ESPript: analysis of multiple sequence alignments in PostScript.Bioinformatics, 1999